Cargando…

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle

OBJECTIVE: Migraine, endometriosis, and the comorbidity of both are frequent pain disorders of special relevance for women. The neuropeptide calcitonin gene‐related peptide (CGRP) is critically involved in migraine, and circumstantial evidence suggests a role in endometriosis. We assessed CGRP level...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raffaelli, Bianca, Overeem, Lucas Hendrik, Mecklenburg, Jasper, Hofacker, Maxi Dana, Knoth, Henriette, Nowak, Claus Peter, Neeb, Lars, Ebert, Andreas Dietmar, Sehouli, Jalid, Mechsner, Sylvia, Reuter, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164854/ https://www.ncbi.nlm.nih.gov/pubmed/33934575 http://dx.doi.org/10.1002/acn3.51360

Ejemplares similares

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2020)

Patients’ and Health Care Workers’ Perception of Migraine Images on the Internet: Cross-sectional Survey Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Endometriosis and Opioid Receptors: Are Opioids a Possible/Promising Treatment for Endometriosis?
por: Guan, Qihui, et al.
Publicado: (2023)

Mechanisms of peripheral sensitization in endometriosis patients with peritoneal lesions and acyclical pain
por: Velho, Renata Voltolini, et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Neurogenic Inflammation in the Context of Endometriosis—What Do We Know?
por: Velho, Renata Voltolini, et al.
Publicado: (2021)

Post-operative management and follow-up of surgical treatment in the case of rectovaginal and retrocervical endometriosis
por: Abesadze, Elene, et al.
Publicado: (2020)

Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Sex Hormones and Calcitonin Gene–Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Chronic Pelvic Pain in Endometriosis: Cross-Sectional Associations with Mental Disorders, Sexual Dysfunctions and Childhood Maltreatment
por: Netzl, Johanna, et al.
Publicado: (2022)

Pelvic floor hypertension: possible factors for pelvic floor tenderness in endometriosis patients—a pilot study
por: Muallem, Jumana, et al.
Publicado: (2023)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
por: Ocheretyaner, Eric R, et al.
Publicado: (2022)

Determining the Evolution of Headache Among Regular Users of a Daily Electronic Diary via a Smartphone App: Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
por: Hong, Ja Bin, et al.
Publicado: (2023)

Nociceptin/Orphanin FQ Opioid Peptide-Receptor Expression in the Endometriosis-Associated Nerve Fibers—Possible Treatment Option?
por: Guan, Qihui, et al.
Publicado: (2023)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Calcitonin Gene-Related Peptide (CGRP) in Cerebrovascular Disease
por: Edvinsson, Lars
Publicado: (2002)

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache
por: Carmine Belin, Andrea, et al.
Publicado: (2020)

Study Design and Protocol of a Randomized Controlled Trial of the Efficacy of a Smartphone-Based Therapy of Migraine (SMARTGEM)
por: Oliveira Gonçalves, Ana Sofia, et al.
Publicado: (2022)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience
por: Silvestro, Marcello, et al.
Publicado: (2021)

Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
por: Jamaluddin, Aqfan, et al.
Publicado: (2022)

Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
por: Muddam, Meghana Reddy, et al.
Publicado: (2023)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
por: Vogler, Birgit, et al.
Publicado: (2023)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8iu2egqrbhcnief54tm8npm8gb